23rd Annual Duke Nicotine Research Conference

Addiction to cigarette smoking is complex, and presents an interaction of a variety of behavioral and pharmacological components. Effective smoking cessation treatments may therefore be best achieved by combination approaches that address these interacting components. These approaches include pharmacotherapies that address the various neurotransmitter systems affected by nicotine, such as cholinergic, serotonergic, dopaminergic, and noradrenergic circuits. Also important for smoking cessation efficacy are combination behavioral strategies including those affecting cognitive and emotional function, craving, and secondary reinforcement. Co-morbid mental illness must also be taken into account in designing effective treatments. This daylong conference will bring together leaders in smoking cessation treatment who have developed combination therapies to address the formidable barriers faced by smokers attempting to quit. Findings will be presented and discussed relating to the efficacy of current combination treatment approaches as well as underlying pharmacological mechanisms. Attendees will gain an understanding of pragmatic approaches to treatment as well as an understanding of neuropharmacologic mechanisms that can further the development of innovative, more effective strategies in the future.